Speaker
Lisa Monteggia
Appearances over time
1 episodes
Episodes
1
Podcasts
Quotes & moments
Depression affects over 280 million people worldwide, making it a leading global health crisis.
Many individuals diagnosed with depression do not have decreased serotonin — they have normal levels, contradicting the chemical imbalance narrative.
Unlike SSRIs which take weeks to work, ketamine produced rapid antidepressant effects within hours in clinical observations.
Lisa Monteggia's lab has been studying ketamine and its antidepressant properties for more than 15 years.
SSRIs increase serotonin quickly but their antidepressant effects take weeks to manifest, a delay scientists still cannot fully explain.
Depression is the leading cause of disability in the United States, measured as loss of productivity for individuals, families, and society.
Ketamine works on the glutamate neurotransmitter system — responsible for fast brain communication — rather than on serotonin like SSRIs.
Counterintuitively, ketamine blocks glutamate transmission rather than activating it, and this blocking action is what triggers synaptic plasticity.
The antidepressant effect of ketamine is not permanent — it typically lasts a few days before waning, requiring researchers to find ways to sustain it.
Ketamine has been most studied in patients who do not respond to SSRIs, including those who have gone without effective treatment for decades.
Ketamine's antidepressant effect is driven by synaptic plasticity — the brain's ability to strengthen neural connections — not by altering neurotransmitter levels.
The new research framing shifts the narrative from depression as a chemical deficiency to a brain that is 'stuck' and needs to adapt, removing the stigma of being broken.
A low-dose ketamine study found something no one expected: antidepressant relief within hours. Before this, scientists didn't even think rapid antidepressant effects were biologically possible.
The dominant explanation for depression — that it stems from low serotonin — turns out to be largely a myth. Most people with depression have completely normal serotonin levels, meaning decades of treatment narrative have been built on a shaky foundation.
Ketamine doesn't raise serotonin. It blocks glutamate — the brain's fast-communication system — and this blocking paradoxically triggers synaptic plasticity, strengthening neural connections. The brain doesn't get fixed; it learns to adapt.
The old story said depressed people were chemically broken. The new story, driven by ketamine research, says their brains are stuck. That's not a semantic difference — it changes how patients see themselves and how treatment is designed.
Ketamine's antidepressant effect lasts only a few days before fading. Researchers are now exploring how to extend that window — through therapy during the plasticity phase, other drugs, or brain stimulation — so patients don't need repeated treatments.
A patient who had failed to respond to SSRIs described living in a dark room with no windows before ketamine treatment. After taking it, they didn't feel cured — but they could see a door. That shift from despair to possibility is what the science is chasing.
Depression has driven some of humanity's most moving creative work — Picasso's Blue Period, Eric Clapton's 'Tears in Heaven,' countless poems and songs. But major depression is far more than sadness: it's the dulling of all emotion.
The goal isn't just to treat today's patients — it's to build better tools for the next generation. Monteggia's lab and others are working to make ketamine safer, extend its effects, and help it reach more people globally.
Depression affects over 280 million people globally and is the leading cause of disability in the United States. Everyone in any given room almost certainly knows someone affected, whether they know it or not.
New ketamine science doesn't invalidate SSRIs. They remain life-saving, first-line treatments for most people with depression. Monteggia's explicit message: if you are on an SSRI, keep taking it.
Analysis
What they talk about
- Health & Fitness 83%
- Science 17%
